Literature DB >> 1975176

CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis.

M Linker-Israeli1, F P Quismorio, D A Horwitz.   

Abstract

The cellular requirements for B cell hyperactivity in systemic lupus erythematosus (SLE) were studied. Removal of either CD8+ or CD4+ lymphocyte markedly decreased the spontaneous in vitro production of polyclonal IgG and of antigen-specific (anti-double-stranded DNA and antinucleoprotein) antibodies by SLE peripheral blood mononuclear cells (PBMC). The CD8+ lymphocytes that sustained IgG production were CD3+, HLA-DR+, and their activity was abrogated by preincubation with anti-HLA-DR monoclonal antibody. When both CD4+ and CD8+ cells were removed, the readdition of either subset partially restored polyclonal IgG production, but both cell subsets were required to reconstitute autoantibody production. Purified SLE B cell cultures, which generated only 15% of the IgG produced by unseparated PBMC, were fully reconstituted only by mixtures of CD4+ with CD8+ cells, and with CD8-, CD4-, CD16+ cells. At least part of the support for spontaneous IgG production can be attributed to endogenous interleukin-2 and interleukin-6.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975176     DOI: 10.1002/art.1780330823

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

1.  Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression.

Authors:  Anthony D Foster; Mark Haas; Irina Puliaeva; Kateryna Soloviova; Roman Puliaev; Charles S Via
Journal:  Clin Immunol       Date:  2010-05-06       Impact factor: 3.969

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  T cells of lupus and molecular targets for immunotherapy.

Authors:  S K Datta; A Kaliyaperumal; A Desai-Mehta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

4.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

Review 6.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

7.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

Authors:  P E Spronk; B T vd Gun; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Characteristics of immunocompetent cells in synovial membranes from multiple sites in patients with rheumatoid arthritis.

Authors:  J G Hanly; D Pledger
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

10.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production.

Authors:  A Desai-Mehta; L Lu; R Ramsey-Goldman; S K Datta
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.